Journal of Clinical Oncology
Articles in this Issue
RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.
TPS5640 Background: Patients with advanced epithelial ovarian cancer (EOC) treated with neoadjuvant platinum-based chemoth...
Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: A real-world study.
3052 Background: Minimal residual disease (MRD) detected using circulating tumor DNA (ctDNA) is associated with increased...
Prognostic significance of teratoma components in germ cell tumor patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
5028 Background: The prognostic significance of a teratoma component in relapsed or refractory germ cell tumors (GCT) trea...
Multidisciplinary care in head and neck squamous cell carcinoma: A retrospective analysis at a safety-net hospital.
e18117 Background: Optimal HNSCC management requires coordinated multidisciplinary care including dental evaluation, nutri...
External validation of new prostate cancer risk groups by PSMA-PET (PPP3).
5112 Background: Previously, we proposed novel risk group definitions for prostate cancer patients based on Prostate-Speci...
Role of transcript-based HER2 quantification in classification and determining therapeutic eligibility.
e15195 Background: Immunohistochemistry (IHC) is widely used to determine human epidermal growth factor receptor 2 (HER2)...
Understanding perceptions and barriers to clinical trial participation in multicultural communities.
e13502 Background: Racial, ethnic, and linguistic minorities remain underrepresented in clinical trials. While structural...
Updated efficacy, safety, and exploratory biomarker analyses of a phase II trial of abemaciclib plus hormonal therapy in recurrent ovarian (OC) and endometrial cancer (EC).
5516 Background: We evaluated abemaciclib with hormonal therapy in patients with estrogen receptor positive (ER+) EC, low-...
Use of subtype-specific patterns of clinically relevant antibody–drug conjugate targets in sarcoma to guide precision oncology strategies.
11549 Background: Sarcomas are rare, biologically heterogeneous malignancies with limited targeted treatment options. Anti...
The trade-offs between efficacy and toxicity: Real-world outcomes of dapsone vs atovaquone for pneumocystis prophylaxis in hematologic malignancies.
e18549 Background: Patients with Hematologic malignancies and multiple myeloma are at increased risk for...
A prospective, single-arm, single-center observational clinical study on envafolimab (PD-L1 inhibitor) in combination with XELOX for neoadjuvant treatment of locally advanced colon cancer.
e15654 Background: Accumulating evidence supports the application of neoadjuvant chemotherapy for locally advanced colon c...
Evaluation of a co-designed nurse-led geriatric oncology multidisciplinary model in treatment-naive older adults with solid cancers.
1661 Background: Integration of geriatric assessment into cancer care improves outcomes for older adults but remains limit...
Real world efficacy of cetuximab plus chemotherapy as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma.
e18032 Background: Head and neck squamous cell carcinoma (HNSCC) represent a major therapeutic challenge due to its biolog...
Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.
1042 Background: The primary analysis of the phase 3 HER2CLIMB-05 study (NCT05132582) showed the addition of TUC to 1L mai...
Matching-adjusted indirect comparison (MAIC) for belantamab mafodotin (belamaf) with pomalidomide and dexamethasone (BPd) vs daratumumab with pomalidomide and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM).
e19574 Background: BPd is approved for patients (pts) with RRMM in multiple countries based on results of the phase 3 DREA...
Osimertinib in the treatment of EGFR mutation–positive advanced non-small cell lung cancer: A meta-analysis.
e20723 Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TK...
Next-generation ADCs and emerging conjugate platforms in breast cancer: a ClinicalTrials.gov landscape analysis.
e15026 Background: Antibody–drug conjugates (ADCs) are reshaping breast cancer management, yet their rapid proliferation r...
A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ <sup>212</sup> Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.
9525 Background: Melanocortin-1 receptor (MC1R) is a novel target for radiopharmaceutical therapy and is highly expressed...
Phase 1, open-label clinical trial to treat stage IV cancer patients harboring multiple patient-specific mutated cell surface proteins with chimeric antibodies.
TPS2672 Background: Despite the advent of multiple classes of systemic cancer treatments, tumor recurrence and subsequent...
Quantitative assessment of tumor shedding using AI-derived radiographic tumor burden and quantified liquid biopsy in advanced gastrointestinal cancers.
3063 Background: Radiographic imaging remains the clinical standard for assessing cancer treatment response; however, it l...
Efficacy and safety of HER2-targeted tyrosine kinase inhibitors in <i>HER2</i> -mutant non–small cell lung cancer: A systematic review and meta-analysis.
e20772 Background: HER2-targeted tyrosine kinase inhibitors (TKIs) represent a new oral targeted therapy class in HER2-mut...
Comprehensive genomic landscape of osteosarcoma: Systematic review and analysis of 1,058 patients across 20 studies with therapeutic implications from the Fight Osteosarcoma Through European Research (FOSTER) Consortium.
10032 Background: Osteosarcoma exhibits profound genomic complexity, complicating biomarker discovery. Although advances i...
Validation and enhancement of the PROACCT model for predicting 30-day acute care events following outpatient systemic therapy using granular health care utilization variables.
e23243 Background: Acute care events within 30 days of outpatient systemic therapy (ACE30)are common, costly, and potentia...
Early toxicity and temporal mortality patterns following bispecific T-cell engager therapy: A real-world multicenter analysis.
e23336 Background: Bispecific T-cell engagers are increasingly used across hematologic malignancies and, more recently, so...
Pan-cancer prevalence, molecular landscape, and prognostic impact of <i>CCNE1</i> amplification across 76,046 malignancies.
3125 Background: CCNE1 amplification ( CCNE1 amp) is an oncoge...